Artivion Inc (AORT)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $931.88M
Last updated: Nov 17, 2026 at 4:15 PM ET
Artivion Inc (AORT) Stock Chart
Artivion (AORT) has a latest price of $18.27 on Nov 17, 2026, 62.1% below its 52-week high of $48.25. Its price fell 60.0% over the past 12 months. The month-end price rose 32.8% over the 10 years through Oct 2026, a compound annual rate of 2.9%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $46.66 in Nov 2025 and its lowest $11.16 in Oct 2022, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart AORT with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for AORT.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 36.6%, and over 6 months it fell 19.6%. The month-end price rose 77.2% over the 3 years through Oct 2026, a compound annual rate of 21.0%.
| Period | Change |
|---|---|
| 1 month | -18.0% |
| 3 months | -36.6% |
| 6 months | -19.6% |
| 12 months | -60.0% |
| 12 months, with dividends | -60.0% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +77.2% | +21.0% |
| 5 years | +9.4% | +1.8% |
| 10 years | +32.8% | +2.9% |
Price by Year
Its best calendar year was 2024, when the price rose 59.9%, and its weakest was 2022, when it fell 40.4%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $22.58 | -50.5% |
| 2025 | $45.61 | +59.5% |
| 2024 | $28.59 | +59.9% |
| 2023 | $17.88 | +47.5% |
| 2022 | $12.12 | -40.4% |
| 2021 | $20.35 | -13.8% |
| 2020 | $23.61 | -12.8% |
| 2019 | $27.09 | -4.5% |
| 2018 | $28.38 | +48.2% |
| 2017 | $19.15 | 0.0% |
Trading Range
The price is 19.2% below its 50-day average of $22.61 and 35.0% below its 200-day average of $28.12.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $18.27 | |
| 52-week high | $48.25 | -62.1% |
| 52-week low | $18.11 | +0.9% |
| 50-day average | $22.61 | -19.2% |
| 200-day average | $28.12 | -35.0% |
Price Risk
Over 3 years, its largest fall from a peak was 61.6%.
| Measure | Value |
|---|---|
| 1-year beta | 0.37 |
| Largest fall, 1 year | -61.3% |
| Largest fall, 3 years | -61.6% |
Valuation
Artivion traded at 72.4x earnings at the end of 2025, against a 10-year median of 86.3x.
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About AORT
What is AORT's 1-year price change?
Artivion's price fell 60.0% over the past 12 months. With dividends included, the 12-month total return was -60.0%.
What is AORT's 5-year price change?
Artivion's month-end price rose 9.4% over the 5 years through Oct 2026, a compound annual rate of 1.8%. These figures leave out dividends.
What is AORT's 52-week high and low?
Artivion's 52-week high is $48.25 and its 52-week low is $18.11. Its latest price of $18.27 on Nov 17, 2026 is 62.1% below the high.
What is AORT's beta?
Artivion's 1-year beta against the S&P 500 is 0.37, so its price has moved less than the market over the past year. Its largest fall from a peak over the past year was 61.3%.
Is the AORT chart free?
Yes. Advanced Charting for AORT is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
AORT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts